FRAMINGHAM, MA--(Marketwire - November 14, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced financial results for the third quarter ended September 30, 2008. For the three months ended September 30, 2008, the Company reported a net loss of $157,472, or $0.01 per share, compared with a net loss of $667,441, or $0.05 per share, in the prior year. For the nine months ended September 30, 2008, the Company reported a net loss of $1,536,209, or $0.09 per share, compared with a net loss of $3,138,065, or $0.25 per share, in the prior year. The decreased loss for such period resulted primarily from decreased clinical development expenses related to the clinical trials of IoGen™, employee compensation and investor relations expenses, partially offset by increased stock-based compensation.
